Objective To determine if the use of magnesium sulphate postdelivery reduces the risk of eclampsia in women with severe pre-eclampsia exposed to at least 8 hours of magnesium sulphate before delivery.
Introduction
Pre-eclampsia is a condition unique to pregnant women, with multisystem involvement and characterised by generalised vasospasm. It affects close to 8% of women during the second half of pregnancy.
1 Between 1 and 3% of women with pre-eclampsia can develop generalised convulsions or eclampsia, with higher frequencies in developing countries. [2] [3] [4] A review determined a frequency of eclampsia of 2% in women with severe pre-eclampsia, 5 and a recent study from Latin America had a frequency as high as 5% in women with pre-eclampsia. 6 Consequences of eclampsia include bronchospasm with aspiration, cerebral haemorrhage, renal insufficiency, abruption, embolism, and maternal and perinatal death. These women may also require care in an intensive care setting, assisted ventilation and can have prolonged hospitalisation. [7] [8] [9] [10] Eclampsia can occur at any time during the second half of pregnancy, during labour and delivery, and postpartum [2] [3] [4] 8 with 72-86% of cases occurring antepartum or during delivery. [9] [10] [11] To prevent eclampsia in women with pre-eclampsia two strategies are proven to work: pregnancy interruption and the use of magnesium sulphate. 12, 13 To prevent eclampsia postpartum , magnesium sulphate is recommended but the evidence for this is questionable.
14,15 Because 14-28% of eclampsia occurs postpartum, 9, 10 it is necessary to determine the best strategy to prevent it. The minimal dose of magnesium sulphate necessary to prevent eclampsia during pregnancy and postpartum is not known. A randomised clinical trial comparing magnesium sulphate with Nimodipine, demonstrated that after an initial loading dose and maintenance of magnesium sulphate for 8 hours before delivery and continuation of this medication for an additional 24 hours postpartum, no eclampsia was seen postpartum. 3 It is not clear in this study if the lack of eclampsia postpartum was due to the use of magnesium sulphate before delivery or the use of this medication for an additional 24 hours postpartum. In contrast, one arm of the MAGPIE study that evaluated the use of magnesium sulphate in the postpartum period did not demonstrate benefit in reducing eclampsia postpartum once this medication was started postdelivery. 2 The objective of our study is to investigate if the initial load and maintenance of magnesium sulphate for a minimum of 8 hours before delivery requires an additional maintenance dose of magnesium sulphate for 24 hours after delivery, to prevent postpartum eclampsia.
Methods

Participants and study design
A randomised clinical multicentre, in parallel and open study, was conducted between December 2014 and November 2015, in nine tertiary-care maternity teaching institutions in Latin America. These centres had experience in managing patients with severe pre-eclampsia and had expertise in conducting clinical trials.
Singleton or twin gestations with the diagnosis of severe pre-eclampsia or superimposed pre-eclampsia with severity criteria over 20 weeks of gestation were invited to participate in the MAG-PIP (MAGnesium Postpartum In Preeclampsia) study.
Severe pre-eclampsia was diagnosed if the patient had a blood pressure of ≥ 140/90 mmHg at least twice, 4 hours apart with the presence of proteinuria ≥ 0.3 g, or even no proteinuria if in addition there was the presence of one of the following findings: severe hypertension (systolic ≥ 160 mmHg or diastolic ≥ 110 mmHg); symptoms such as severe headache, visual disturbances, epigastric pain; and/or laboratory abnormalities [increase in serum creatinine, thrombocytopenia, elevated liver transaminases, abnormal coagulation studies, without the presence of HELLP (haemolysis, elevated liver enzymes and low platelet count) syndrome]. If the woman was chronically hypertensive and presented with severe hypertension (systolic ≥ 160 mmHg or diastolic ≥ 110 mmHg), with presence of proteinuria ≥ 0.3 g; symptoms such as severe headache, visual disturbances, epigastric pain; and/or laboratory abnormalities (increase in serum creatinine, thrombocytopenia, elevated liver transaminases, abnormal coagulation studies, without the presence of HELLP syndrome), then she was considered to have superimposed pre-eclampsia with severity criteria.
Exclusion criteria included: eclampsia, HELLP syndrome, epilepsy, severe pre-eclampsia with additional complications including acute or chronic renal insufficiency, pulmonary oedema, uncontrolled diabetes mellitus, autoimmune disorders and hypertensive encephalopathy.
Eclampsia was defined as the presence of a generalised convulsion secondary to pre-eclampsia in a women in whom no other causes for convulsion can be found.
Postpartum haemorrhage was defined as the presence of vaginal bleeding > 500 ml during delivery and/or in the first 24 hours postpartum or bleeding > 1000 ml during caesarean section or for the next 24 hours.
Respiratory insufficiency was defined as difficulty breathing characterised by tachypnoea or dyspnoea, and low oxygen saturation (< 90%), from birth to hospital discharge.
The hospital ethics committees and research authorities approved the study before patient recruitment. The research coordinator in each centre monitored the compliance with the study protocol and asked for immediate information in the case of eclampsia with close follow up of each case. All women provided written informed consent.
Randomisation
All women received verbal and written information about the study. After discussing the MAG-PIP study and obtaining signed informed consent, women were randomised to continue magnesium sulphate for 24 hours postpartum after vaginal delivery or caesarean/section (control group) or to not receive magnesium sulphate postpartum (study group), in a 1:1 ratio.
All women received information (verbal and written) about the benefits and risks of receiving, or not, magnesium sulphate and were told of the management protocol in the case of a convulsion. The randomisation was done using a computer program in blocks of four and placed in sealed envelopes. The research coordinator in each hospital did not have access to the randomisation sequence. This was an open trial to minimise costs and logistical organisational concerns.
Interventions
All women in this study received 4 g of magnesium sulphate intravenously as a loading dose and were kept on a maintenance dose of 1 g per hour intravenously.
Every woman with severe pre-eclampsia who had received at least 8 hours of continuous magnesium sulphate to prevent a convulsion before delivery was considered a candidate for the study. The women received an explanation of the study and if accepted and after informed consent the randomisation was carried out hours before or at the time of birth.
All women received routine postpartum care given to patients with severe pre-eclampsia. They were observed and monitored closely in an obstetric unit (in some hospitals in an intensive care unit and in others in a high-care bed), with constant monitoring of blood pressure, and other vital signs and symptoms. Women randomised to magnesium sulphate had a Foley catheter and were on strict bed rest. Women randomised to no magnesium sulphate were allowed to ambulate and breastfeed as tolerated. Vital signs were monitored continuously in both groups. In the presence of a hypertensive crisis during pregnancy or postpartum (systolic ≥ 160 mmHg or diastolic ≥ 110 mmHg), intravenous hydralazine 5 mg was given every 20 minutes, up to a maximum of five doses; or intravenous labetalol 20 mg with duplication of the dose 20 minutes later and up to a third dose of 80 mg given if hypertension was persistent. The use of nifedipine was also allowed in a dose of 10 mg orally every 20 minutes for hypertensive crisis. The use of oral antihypertensive medications postpartum without hypertensive crisis was at the discretion of the treating physician, the oral medications usually used postpartum are nifedipine, a-methyl dopa and amlodipine. In our hospitals, routine oral antihypertensive drugs are not applied to patients with severe pre-eclampsia during postpartum.
They are usually administered to women with persistent symptoms, with co-morbidities and to women who undergo postpartum hypertensive crises.
Baseline data and maternal complications were recorded as per the study protocol.
In the case of a convulsion, if the woman was in the magnesium sulphate group, an additional 4 g of magnesium sulphate load was given intravenously over 5-10 minutes, and the maintenance dose of 1-2 g/hour was continued. If the woman was not receiving magnesium sulphate, then a loading dose of 4 g of magnesium sulphate was given over 5-10 minutes and the patient was kept on a maintenance continuous dose of 1-2 g/ hour of magnesium sulphate according to the hospital protocol for a total of 24 hours. These women received intense surveillance that in many hospitals included admission to the intensive care unit for observation and management.
Routinely in our hospitals, walking is allowed around 12 hours after caesarean section. However, in pre-eclampsia with magnesium sulphate, walking is allowed after receiving 24 hours of magnesium sulphate, independent of the anaesthesia used.
Statistical analysis
The primary outcome of the study was the presence of a convulsion in the first 24 hours postpartum. The secondary outcomes included complications such as: postpartum haemorrhage, respiratory difficulty, maternal mortality, total time on magnesium sulphate before delivery, postpartum time of convulsion, number of convulsions, admission to intensive care unit secondary to a complication, use of antihypertensive medications postpartum, use of antihypertensives for hypertensive crisis, convulsing 24 hours postpartum, time to initial ambulation, time to initiate breastfeeding.
The number of women needed for the study was calculated for a no-inferiority study and based in the primary outcome, the presence of eclampsia in the first 24 hours postpartum. The calculations were based on the MAGPIE study 2 that showed a 58% reduction in eclampsia in patients receiving magnesium sulphate, and a 2% chance of eclampsia in women with severe pre-eclampsia not receiving magnesium sulphate. 5 Assuming that the possibility of convulsion is similar without using magnesium sulphate compared with its use for 24 hours postpartum, as long as the patient had received at least 8 hours of magnesium sulphate before delivery, and defining the 95% CI of noninferiority at a level inferior to the 10% using an a error of 5% and power of 90%, the study required 511 women with severe pre-eclampsia per group. To account for possible protocol alterations or losses, an additional 10% of women were needed to continue to have a power of 90%, giving a total of 560 women per group, and a total study population of 1120.
The basal characteristics of each participant in each group were compared using the Student's t test for continuous variables with normal distribution. Dichotomous variables were compared using Fisher's exact test and chisquare test when appropriate. P values < 0.05 were considered statistically significant. Only the primary objective was evaluated in terms of non-inferiority.
The other comparisons were analysed for superiority and were considered statistically significant at a two-tailed value of a = 0.05.
The statistical analysis was performed with EPI INFO version software #7 (CDC, Atlanta, GA, USA) with the intention-to-treat principle.
There was no correlation between financial support for the study and core outcomes studied. No woman received financial incentives to participate. The support was used for trial-related activities.
This study was registered under ClinicalTrials.gov # NCT02307201
Results
During 11 months, in nine maternity hospitals in Latin America, 1113 women consented to participate in the MAG-PIP study. Eight randomised women received < 8 hours of magnesium sulphate before delivery; of these, five were randomised to the no magnesium sulphate postpartum group. In five women randomised to receive no magnesium sulphate postpartum, their medication was continued for 3-6 hours secondary to orders by the treating physician after incorrect interpretation of the study protocol. All of these women were included in the final analysis. A total of 555 women were randomised to receive magnesium sulphate postpartum (control group) and 558 were randomised to not receive magnesium sulphate postpartum (study group). The CONSORT patient flow diagram is given in Figure 1 . Table 1 shows the baseline characteristics of the studied population. Ninety percent had severe pre-eclampsia without the presence of hypertension before gestation and 59% were nulliparous. In all, 52% of women received an antihypertensive medication in oral or parenteral form to control blood pressure before randomisation, without significant differences between the groups. In addition, 24% of the women had small-for-gestational-age infants. Only 39% of women in either group had a vaginal delivery.
There was no significant difference in the primary objective, the rate of eclampsia in the first 24 hours postpartum, between the groups, Table 2 . One patient (0.18%) in the magnesium sulphate group and 2 (0.36%) in the no magnesium sulphate group convulsed, without reaching the established no-inferiority level.
Furthermore, there were no significant differences between the groups in the rate of complications or for a particular complication. Two secondary objectives that show differences were the time of ambulation, being shorter by 6 hours in the no magnesium sulphate postpartum group (P < 0.001) and time to initiate breast feeding, 7 hours shorter (P < 0.001) in the no magnesium sulphate group.
One woman developed syncope 49 hours postpartum. This woman was a primigravida who did not receive magnesium sulphate postpartum, and had multiple hypertensive crises 24 hours postdelivery. Healthcare personnel did not witness this syncopal episode so it is not possible to determine if this was a convulsion or not. Even if this syncopal episode is added as a convulsion to the no magnesium sulphate group, the primary objective of the study does not change (relative difference -0.36; 95% CI À1.06 to 0.34; P = 0.62).
In relation to the three women who had eclampsia in this study (Table 3 ) -the three women convulsed only once within 6 hours postpartum and did not have any further complications. The two women that convulsed and were not receiving magnesium sulphate received a loading dose of 4 g of magnesium sulphate and were kept on a maintenance dose of 1 g per hour for an additional 24 hours. In this study the total rate of eclampsia was 0.27%. There were no maternal deaths and all women left the hospitals in good condition.
Discussion
Main findings
This randomised controlled trial demonstrates that the frequency of eclampsia postpartum in women receiving magnesium sulphate maintenance postpartum is not inferior compared with women not receiving magnesium sulphate postpartum, in women with severe pre-eclampsia who were loaded with magnesium sulphate and were receiving this medication for at least 8 hours before delivery. Furthermore, without using magnesium sulphate, times to ambulation and breastfeeding were shorter, with benefits to both mother and baby.
Strengths
Some of the strengths of this study include: it is a randomised clinical trial with a primary objective that is easy to evaluate. It was a multicentre study in countries with high frequencies of pre-eclampsia/eclampsia.
Limitations
The major limitation to this study was that it was an open trial and not blinded due to costs and logistical organisational concerns. We feel that because the primary variant was so clear and objective, this limitation is of no great consequence. Another limitation of this study is the sample size. It was based on a much higher eclampsia rate than observed in the study in the control group (2% versus 0.38%), possibly because both groups received magnesium sulphate. Hence, the results should be treated with some caution due to the small number of events.
Interpretation (in light of other evidence)
According to the MAGPIE study, the largest study to date of women with pre-eclampsia in which the incidence of eclampsia was studied, 1.9% of women with pre-eclampsia not treated with magnesium sulphate convulsed. 2 In the *Non-inferiority comparison, difference (95% CI) = À0.18 (À0.79 to 0.43). Only this outcome was compared using non-inferiority. P = 1.0 **Severe hypertension: diastolic blood pressure ≥ 110 mmHg or systolic blood pressure ≥ 160 mmHg.
Belfort et al. study, 3 2.6% of women without magnesium sulphate convulsed compared with 3.2% in a study from South Africa. 4 A recent study from Brazil had an incidence of 5% eclampsia in patients with severe pre-eclampsia. 6 It is clear that women with severe pre-eclampsia not receiving magnesium sulphate are at greater risk of having a convulsion, this varies between 1.9 and 3.2%. The same studies demonstrate that the use of magnesium sulphate predelivery and postpartum is associated with an incidence of eclampsia between 0.3 and 0.8%. [2] [3] [4] [5] Our clinical trial demonstrates that in women with severe pre-eclampsia who have been loaded with magnesium sulphate and a maintenance dose of this medication for 8 hours before delivery; continuing or not continuing the magnesium sulphate infusion postpartum conveys a similar risk of convulsion. This percentage of eclampsia is similar to the one observed in studies that have kept the magnesium sulphate ongoing for 24 hours. [2] [3] [4] The three women who had eclampsia in our study, convulsed only once and within the first 6 hours postpartum. Based on this fact we can extrapolate that either strategy: to continue the magnesium sulphate or not postpartum, is 100% effective in reducing eclampsia after the first 6 hours postpartum and in 100% a second convulsion was avoided, as long as the women had received at least 8 hours of magnesium sulphate before delivery.
The therapeutic mechanism of action of magnesium sulphate has not been elucidated completely. 5, 12 The half-life of magnesium is 4 hours. Approximately half of the infused magnesium moves into bone and other cells within 1.5 hours. Linear regression analysis has not shown a correlation between ionised magnesium and total magnesium in pre-eclampsia; however, 90% elimination occurs by 24 hours postinfusion. Interestingly, elimination increases 20-fold during infusion. 5, 12 The secondary objectives evaluated in this trial included maternal complications such as maternal death, postpartum haemorrhage, respiratory insufficiency, antihypertensive need, severe hypertension and hypertensive encephalopathy; we did not find a significant difference in these complications between giving and not giving magnesium sulphate postpartum. In addition, the rate of complications seen in our trial is similar to those observed in previous studies using magnesium sulphate. 2, 3 The lack of differences in complications could be because all participants in this trial received a minimal dose of magnesium sulphate before delivery and this dose could be responsible for the rate of complications seen in postpartum.
In many hospitals in the world, in particular in Latin America, woman who are receiving magnesium sulphate postpartum are kept on strict bed rest for 24 hours. In addition, they are not allowed to breastfeed while receiving magnesium sulphate. We expected in our study that the rates of time of starting ambulation and time of starting breastfeeding would be shorter in the patients not receiving magnesium sulphate postpartum, based on the way patients are managed, but these differences were significantly different, suggesting that if we do not reduce the risk of eclampsia by given magnesium sulphate for 24 hours postpartum, then without its use we can benefit mother and baby, by allowing early ambulation and early breastfeeding.
We know that 80% of convulsions in women with preeclampsia occur during gestation, labour and delivery.
9,10 If we concentrate on strategies to reduce eclampsia during pregnancy and delivery, we can be 80% effective. Clearly, the principal strategy when confronted with a woman with severe pre-eclampsia should be hospitalisation with a correct diagnosis and interruption of gestation in the case of severe pre-eclampsia.
If not using magnesium sulphate postpartum does not result in inferiority compared with its use, it is important to consider the secondary effects related to its use. In this study, exposure to postpartum magnesium sulphate resulted in a 6-hour delay in patient ambulation. This could result in a greater risk of thromboembolism, in particular in women who undergo caesarean sections. [16] [17] [18] In this study the rate of caesarean section was very high, > 60%, putting these patients at greater risk. The caesarean delivery rate is two to three times higher for women with pre-eclampsia compared with the non-pre-eclampsia caesarean rate in our hospitals. This is the result of multiple factors including: prematurity, malpresentation, unfavourable cervix, and urgent delivery secondary to maternal and fetal compromise associated to severe pre-eclampsia.
In addition, the time to breastfeeding was delayed by 7 hours, going against the principle of the benefits of immediate breastfeeding after birth. 19, 20 Other known complications of magnesium sulphate exposure include: maternal somnolence, muscular weakness and magnesium toxicity. 21 The use of a Foley catheter increases the risk of infection. 16 It is also clear that keeping a patient on magnesium sulphate postpartum is more costly and requires more resources, ranging from specialised personnel to availability of hospital and intensive care beds. 22, 23 It is important to note that 50% of patients in the postpartum period required antihypertensives (same in both groups). The role of antihypertensives in preventing eclampsia requires further study.
In this trial, there were no maternal deaths. Women with more complications were excluded, for example those with HELLP syndrome; in this group of women with severe pre-eclampsia and other complications the magnesium sulphate is necessary.
Conclusion
Woman with severe pre-eclampsia treated with a minimum of 8 hours of magnesium sulphate before delivery possibly do not benefit from continuing the magnesium sulphate for 24 hours postpartum. Lack of use of magnesium sulphate postpartum in these women is not associated with a decrease in eclampsia or maternal mortality. Similar studies or a study with larger sample size are necessary to corroborate these findings. Without using magnesium sulphate, times to ambulation and breastfeeding are shorter with benefits to both mother and baby.
